To provide the information your oncologist is not telling you or doesn't have the time to!
Embark on a comprehensive exploration of colorectal cancer within our dedicated ‘Colorectal Cancer’ subcategory. Focused on providing invaluable insights into this common yet intricate form of cancer, our curated content encompasses a spectrum of information. Navigate through articles, expert perspectives, and the latest advancements in research and treatment options specific to colorectal cancer. Whether you’re seeking guidance on early detection, understanding different stages, or exploring supportive care, our ‘Colorectal Cancer’ subcategory is your trusted resource. Empowering individuals, caregivers, and healthcare professionals, we aim to foster awareness and knowledge to navigate the complexities of colorectal cancer. Join us on a journey towards informed decision-making and proactive colorectal health within this specialized arena of oncology
On December 20, 2024, the FDA granted accelerated approval for a groundbreaking new treatment approach for patients with metastatic colorectal cancer (mCRC) harboring the BRAF V600E mutation. The newly approved regimen combines encorafenib (Braftovi) with cetuximab and mFOLFOX6 (a chemotherapy regimen consisting of fluorouracil, leucovorin, and oxaliplatin). This marks a pivotal step forward in the …
Colorectal cancer remains a significant global health challenge, ranking as the third most common cancer and the second leading cause of cancer-related deaths worldwide. Among metastatic colorectal cancer patients, the subset with microsatellite instability-high (MSI-H) or mismatch-repair–deficient (dMMR) tumors presents unique opportunities for immunotherapy. The recent CheckMate 8HW trial, published in the New England Journal …
Colon cancer treatments have long relied on surgery, chemotherapy, and radiation. However, recent breakthroughs in immunotherapy, particularly for mismatch repair–deficient (dMMR) tumors, are reshaping how certain high-risk cancers are treated. A recent study published in The New England Journal of Medicine provides encouraging data on the effectiveness of neoadjuvant immunotherapy for patients with locally advanced dMMR colon …
In a recent and courageous announcement, actor James Van Der Beek, known for roles in Dawson’s Creek and Varsity Blues, revealed his diagnosis of colorectal cancer. At age 47, Van Der Beek shared that he has been managing this diagnosis privately, taking steps towards treatment with the support of his family. While the specifics indicate …
Immunotherapy has made significant strides in cancer treatment, but microsatellite stable (MSS) metastatic colorectal cancer (mCRC) has long posed a challenge due to its resistance to immune-based therapies. However, promising results from a recent phase 2/3 trial have shown that the individualized neoantigen-directed immunotherapy, GRANITE, may change the outlook for patients with MSS mCRC. This innovative therapy, combined …
Unveiling a New Era in Colorectal Cancer Treatment: The Promise of KRAS G12C Inhibition Colorectal cancer stands as one of the most common and deadly forms of cancer worldwide. Despite advances in treatment, the search for more effective and targeted therapies continues. A significant breakthrough in this quest is the understanding and targeting of specific …
On December 14, 2023, the FDA gave the green light to belzutifan (Welireg, Merck & Co., Inc.), offering new hope for individuals battling advanced kidney cancer. It’s like unlocking a powerful tool after trying different strategies. Understanding Belzutifan’s Power Against Kidney Cancer Imagine your body as a bustling city with the kidneys playing the role …
ASCO 2023 was a ton of fun and lot of learning. In the coming weeks, I’ll share select abstracts that I thought were most important. This article discusses data from a groundbreaking PROSPECT trial which was presented as a Plenary topic at Chicago and published in NEJM last week. Ultimately, this creates more treatment options …
Colon cancer is the third most common cancer worldwide, affecting millions of individuals every year. Currently, the treatment paradigm for resected stage 2 and 3 colon cancer patients typically involves surgery followed by adjuvant chemotherapy to reduce the risk of cancer recurrence. However, the prognosis for these patients varies significantly, with some experiencing a complete …
“How am I doing?”, asked one of my colorectal patients. Ten years ago, I first met John (name changed for privacy), a warm and spirited individual diagnosed with stage 3 colon cancer. After undergoing surgical resection of the primary colon tumor and six months of standard adjuvant chemotherapy with mFOLFOX, John and I optimistically looked …